US SEC Filing Intelligence

Biotech Small-Cap Approvals — August 21, 2026

The review period from August 14-21, 2026, yielded four generic/biosimilar approvals (FALLBACK type) with no NMEs, no label expansions, and no first-in-class agents. All approvals are classified as neutral signals with equal 5/10 strength and materiality scores, confirming this was a low-catalyst window for biotech small-cap exposure. The approvals cover three distinct therapeutic areas—Parkinson's disease (CARBIDOPA/LEVODOPA via Dr. Reddy's), erectile dysfunction/pulmonary hypertension (TADALAFIL via Jubilant), autoimmune/inflammatory disease (TOFACITINIB via Teva), and oncology (CABOZANTINIB via MSN)—with no dominant therapeutic cluster. The highest-conviction signal is Teva's entry into the JAK inhibitor generic market with TOFACITINIB, exposing Pfizer’s XELJANZ franchise to incremental competition, though XELJANZ already faces multiple generic entrants. The key risk is that none of these approvals advance pipeline quality or signal differentiation, and all are incremental commoditization events with limited near-term commercial disruption given generic saturation in these categories.

4 total filings

New Drug Approvals (Original) — August 21, 2026

The week of August 14-18, 2026 produced exclusively biosimilar/generic approvals—zero NMEs, zero label expansions, and four 'Fallback' or generic-type drug approvals. The most notable approvals by sponsor include DR REDDYS LABS LTD’s carbidopa/levodopa and TEVA PHARMS USA’s tofacitinib citrate, representing lower-risk, incremental competitive entries. While no novel therapeutic catalysts emerged, the pure biosimilar/generic cadence signals continued erosion pressure on originator franchises in Parkinson’s disease (carbidopa/levodopa), erectile dysfunction (tadalafil), autoimmune therapy (tofacitinib), and oncology (cabozantinib). Key watch items include TEVA’s ability to capture market share against Pfizer’s Xeljanz and genericization dynamics in the kinase inhibitor class. No major bullish signals were identified; all four approvals are neutral for the investing community.

4 total filings

Federal Construction & Infrastructure Contracts — August 21, 2026

The single contract in this digest, a $149.2 million firm-fixed-price delivery order awarded to HSGS-AMERESCO, LLC by the Department of Veterans Affairs, represents a purely civilian infrastructure play with zero defense exposure. The contract is an energy savings performance contract (ESPC) for VA medical centers, structured as a Service-Disabled Veteran-Owned Small Business set-aside, which limits competitive pressure but also caps scalability. The highest-conviction signal is neutral, reflecting a stable but low-growth revenue stream tied to energy savings verification. Key risks include the fixed-price structure introducing execution risk and the 19-month performance period limiting revenue visibility beyond February 2027.

VA Healthcare & Services Contracts — August 21, 2026

The sole contract in this digest is a $149.2 million firm-fixed-price delivery order awarded to HSGS-AMERESCO, LLC by the Department of Veterans Affairs for energy savings performance contract (ESPC) work at two VAMCs. This is a purely civilian award with zero defense exposure, reflecting stable VA infrastructure spending but with execution risk tied to energy savings verification. The highest-conviction signal is the SDVOSB set-aside, which limits competition but also caps scalability for the contractor. Key risk is the fixed-price structure, which could compress margins if cost overruns occur during the 19-month performance period.

HHS & Healthcare Contracts Intelligence — August 21, 2026

This digest covers a single, large HHS contract awarded to the Albert B. Sabin Vaccine Institute, a nonprofit, for Marburg virus R&D under BARDA. The $263.6 million initial obligation is part of a $1.04 billion, 10-year cost-plus-fixed-fee program, representing 100% civilian biodefense spending. The neutral signal (5/10) reflects limited direct equity exposure due to the nonprofit recipient, but the scale and duration underscore sustained government commitment to pandemic preparedness. Key risk is funding uncertainty across a decade-long performance period, with option exercises as critical monitoring points.

New Federal Contractors — August 21, 2026

The five contracts analyzed, totaling $1.6 billion in obligations, are overwhelmingly civilian (4 of 5), with only one defense-related award. The dominant theme is stable, multi-year IT and infrastructure spending by civilian agencies (GSA, NASA, HHS, VA), with CACI's $674M GSA IT services contract representing the highest-conviction bullish signal due to its cost-plus pricing and competitive win. Key risks include the expired nature of Teledyne Brown's $371M NASA contract (zero future revenue) and the nonprofit status of the Sabin Vaccine Institute's $263M BARDA award, which limits direct equity exposure. Investors should watch for CACI's contract recompete in May 2024 and option exercises on the VA's $149M ESPC award.

Significant Contract Modifications ($10M+) — August 21, 2026

This digest covers $1.6B in aggregate obligations across 6 contracts, with only 1 of 6 being defense-related (Lockheed Martin's $6K DHS award), making this a heavily civilian-focused period. The dominant theme is federal IT and biodefense spending: CACI's $674M GSA IT services award is the highest-conviction signal, providing predictable cost-plus revenue through 2024. However, the aggregate signal strength is low (4.8/10) due to five neutral-rated contracts, including a $372M NASA ISS support contract from Teledyne Brown that has already expired with only $151M actually outlayed. Key risk: the CACI contract shows a negative net outlay (-$415K), which may indicate accounting adjustments or early-stage execution issues that warrant monitoring.

6 total filings

Contract Deobligations Alert — August 21, 2026

This digest covers $1.6 billion in total obligations across six contracts, with a striking 5/6 civilian agency split (GSA, NASA, HHS, VA, NIH) and only one defense-related award (DHS, negligible $6K). The dominant theme is stable, multi-year civilian IT and mission support spending, led by a $674M CACI GSA IT services contract (bullish, low-risk cost-plus pricing) and a $371.5M Teledyne NASA ISS support contract (neutral, expired, under-executed). The highest-conviction signal is CACI's competitive win, signaling durable federal IT demand, but the key risk is the Teledyne contract's actual outlays being less than half of obligations, indicating potential execution or funding issues. Overall, the digest points to robust civilian agency IT and biodefense spending, but with limited direct defense exposure and a neutral-to-bullish signal strength averaging 4.8/10.

6 total filings

Contract Option Exercises — August 21, 2026

Over the single-day period of August 21, 2026, the government exercised options on six contracts totaling $1.60 billion, but only one of six awards was defense-related, signaling a heavy civilian-agency tilt in this stream. The dominant theme is civilian IT and infrastructure modernization, led by a $674M CACI, Inc. cost-plus IT services award from the GSA—the highest-conviction signal due to its low-risk pricing and competitive win. A $372M Teledyne Brown Engineering NASA contract for ISS operations is now expired, contributing zero forward revenue, while a $264M BARDA biodefense contract to a nonprofit limits direct equity exposure. The key risk is the negative net outlay on CACI's contract, which may indicate accounting anomalies or early-stage performance issues that warrant monitoring.

6 total filings

Federal IT & Cybersecurity Contracts — August 21, 2026

This digest covers two civilian agency IT contracts totaling $813M, with zero defense exposure, signaling robust non-DOD federal IT spending. The dominant theme is GSA and NIH IT modernization, led by a $674M CACI cost-plus award from GSA that provides low-risk, predictable revenue but carries an unusual negative outlay requiring monitoring. A $139M NIH cloud services contract to HIGHRISE CONSULTING shows strong execution with 65% already outlayed, indicating low cancellation risk. The highest-conviction signal is CACI's competitive win on technical merit, though the contract's 2019 start and 2024 end date raise re-compete risk. Key watch items include clarifying CACI's negative outlay and tracking HIGHRISE's ability to secure follow-on task orders.

2 total filings

All HHS Contracts — August 21, 2026

The two HHS contracts totaling $402.2 million reveal a civilian-agency focus with a strong biodefense and IT modernization theme. The largest award, a $263.6 million BARDA contract to the nonprofit Sabin Vaccine Institute for Marburg virus R&D, signals sustained government investment in pandemic preparedness but offers no direct equity exposure. The second award, a $138.6 million NIH IT services delivery order to Highrise Consulting, shows stable recurring revenue from cloud support with 65% already outlayed, reducing cancellation risk. Key risks include the long performance period (10 years) for the Sabin contract and potential budget uncertainty under a continuing resolution. The highest-conviction signal is the high utilization rate on the Highrise contract, indicating strong execution and low termination risk.

2 total filings

Mega Contracts Monitor ($100M+) — August 21, 2026

This digest covers $1.60B in obligations across five contracts from August 21, 2026, with only one defense-related award (20% defense/civilian split), signaling a heavy tilt toward civilian agency IT and biodefense spending. The highest-conviction signal is CACI’s $674M GSA IT services win, a bullish, low-risk cost-plus contract that reinforces its federal IT moat, though the negative net outlay (-$415K) warrants monitoring. The dominant theme is civilian IT modernization (CACI, HIGHRISE) and biodefense R&D (Sabin Vaccine Institute), with NASA’s Teledyne Brown contract already expired, offering zero future revenue. Key risk: the $263.6M Sabin contract is with a non-profit, limiting direct equity exposure, while HSGS-AMERESCO’s $149M VA ESPC carries high fixed-price execution risk.

High-Value Federal Grants ($5M+) — August 21, 2026

This digest covers $1.6 billion in federal obligations across five contracts, with only one defense-related award (20% defense mix), signaling a civilian-heavy procurement period led by GSA, NASA, HHS, and VA. The highest-conviction signal is CACI's $674M GSA IT services contract, which offers low-risk cost-plus revenue through 2024 but carries a negative net outlay anomaly requiring monitoring. Key risks include Teledyne Brown Engineering's NASA contract ending in 2022 with no follow-on visibility, and HSGS-AMERESCO's fixed-price VA energy contract exposing it to performance risk. The dominant theme is civilian IT and biodefense spending, with limited direct defense exposure.

General Federal Contracts — August 21, 2026

This digest covers five contracts totaling $1.597 billion, with only one defense-related award (20% of records) and the remainder civilian, primarily from HHS and NASA. The dominant theme is stable, multi-year IT and biodefense spending, with CACI's $674M GSA IT services contract as the highest-conviction signal, offering predictable cost-plus revenue through 2024. Key risks include the expired Teledyne Brown NASA contract ($371.5M) with no follow-on visibility and the nonprofit Sabin Vaccine Institute award ($263.6M) limiting direct equity exposure. Investors should monitor CACI's contract execution and potential recompete, as well as BARDA's option exercises for biodefense funding continuity.

All NASA Contracts — August 21, 2026

This digest analyzes a single NASA contract awarded to Teledyne Brown Engineering, a subsidiary of Teledyne Technologies, valued at $371.5M for ISS mission operations support. The contract is entirely civilian (0% defense-related) and has already ended (December 2022), making it a historical data point rather than a current revenue driver. The highest-conviction signal is the significant gap between the obligated value ($371.5M) and actual outlays ($151.3M), suggesting the contract underperformed relative to its ceiling. The key risk is that this contract represents a past revenue stream with no current contribution, and investors should watch for any follow-on awards to gauge Teledyne's retained position in NASA's manned spaceflight operations.

10 high priority 10 total filings

S&P 500 Technology Sector SEC Filings — August 21, 2026

The 10 filings from the S&P 500 Technology sector on August 21, 2026, reveal a pronounced insider selling pattern among top executives at major cybersecurity and semiconductor firms, including CrowdStrike, Datadog, and AMD, all executed under Rule 10b5-1 plans, which may indicate pre-planned portfolio diversification rather than immediate bearish conviction. Palo Alto Networks' bylaw amendments signal a defensive governance posture ahead of the next annual meeting cycle, potentially to deter activist or shareholder proposals. AppLovin saw multiple C-suite insiders (CEO, CFO, CTO, CLO, Director) engage in tax-withholding share surrenders, a routine but notable cash-out event at a $308.77 price point. No period-over-period financial trends, forward-looking guidance, or capital allocation changes were disclosed in these filings, limiting the ability to derive growth or margin trends. The lack of earnings or operational updates across all filings suggests a quiet period post-earnings season, with insider activity being the primary actionable signal. The concentrated insider selling across high-profile tech names warrants close monitoring for any subsequent negative guidance or sector headwinds.

17 high priority 17 total filings

Nasdaq 100 Stocks SEC Filings — August 21, 2026

The 17 filings from NASDAQ-100 constituents for August 21, 2026, are dominated by insider transactions, revealing a clear pattern of management monetization across several key holdings. The most significant cluster is at **CoreWeave (CRWV)**, where seven top executives (including the CEO, CFO, COO, and CSO) collectively sold over $4.8 million in Class A Common Stock at $91.88, representing a coordinated and material insider liquidation event. This is the most critical development, signaling potential concern about the company's near-term valuation or business trajectory. In contrast, **AppLovin (APP)** shows a non-selling pattern, with four insiders (CEO, CLO, Director, CFO, CTO) only having shares withheld for taxes, indicating no discretionary selling. **Advanced Micro Devices (AMD)** saw its CTO sell $4.52M under a 10b5-1 plan, while **QUALCOMM (QCOM)** and **Gilead Sciences (GILD)** had smaller, planned sales by senior officers. The overall portfolio-level theme is one of insider caution, particularly in the AI-infrastructure and semiconductor sectors, with no bullish insider buying detected across any of the 17 filings. No period-over-period financial comparisons, forward-looking guidance, or capital allocation changes were present in these filings, limiting trend analysis to insider behavior patterns.

20 high priority 18 medium 38 total filings

US Activist Hedge Fund Institutional SEC 13D 13G — August 21, 2026

This digest of 38 SEC filings reveals a period of significant portfolio restructuring and capital reallocation. The most dominant theme is the unwinding of large, long-held positions, highlighted by Liberty Broadband's complete exit from both Charter Communications and comScore following its acquisition by Charter, and the disbanding of the Brera Holdings group. Concurrently, we see aggressive accumulation by activist-leaning funds, particularly Steamboat Capital's rapid build of a 7.1% stake in Medifast and Hyperscale Data's continued buying in Universal Safety Products. A notable pattern of 'passive conversion' is emerging, where entities like Tang Capital and White River Ventures are switching from activist (13D) to passive (13G) filings, signaling a de-escalation of control intentions. Insider activity is mixed; while CEO Eric Singer of Immersion Corp has a large personal stake, the complete exit by Westerly Capital from Harte Hanks and Almitas Capital from multiple positions suggests a lack of conviction in certain names. The data points to a market where sophisticated capital is rotating out of legacy positions and into specific, high-conviction bets, creating both risks and opportunities for investors.